[go: up one dir, main page]

AR062387A2 - El uso de un compuesto derivado de imidazo[1,2-a] piridina, y un medicamento que lo contiene - Google Patents

El uso de un compuesto derivado de imidazo[1,2-a] piridina, y un medicamento que lo contiene

Info

Publication number
AR062387A2
AR062387A2 ARP070103631A ARP070103631A AR062387A2 AR 062387 A2 AR062387 A2 AR 062387A2 AR P070103631 A ARP070103631 A AR P070103631A AR P070103631 A ARP070103631 A AR P070103631A AR 062387 A2 AR062387 A2 AR 062387A2
Authority
AR
Argentina
Prior art keywords
halogen
alkyl
alkoxy
hydroxy
disorders
Prior art date
Application number
ARP070103631A
Other languages
English (en)
Inventor
Vincent Mutel
Jens-Uwe Peters
Juergen Wichmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR062387A2 publication Critical patent/AR062387A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

El uso de un compuesto derivado de imidazo [1,2-a]piridina de formula general (1) en la cual: R1 significa hidrogeno, alquilo (C1-6), halogeno, hidroxi, alcoxi (C1-6); R2 significa hidrogeno, alquilo (C1-6) halogeno, hidroxi, alcoxi (C1-6); y A significa arilo no sustituido o arilo sustituido con uno o más sustituyentes seleccionados entre el grupo que consiste en alquilo (C1-6), halogeno, halogeno-alquilo (C1-6), hidroxi, alcoxi (C1-6), benciloxi, amino, alquilamino (1-6), arilamino, diarilamino o nitro, o significa he-teroarilo no sustituido o heteroarilo sustituido con uno o más sustituyentes seleccionados entre el grupo que consiste en alquilo (C1-6) halogeno, halogeno-alquilo (C1-6), hidroxi, alcoxi (C1-6), benciloxi, amino, alquilamino (C1-6), di-alquil-amino (C1-6), arilamino, diarilamino o nitro, o significa un grupo (1) en donde X es, independientemente uno de otro, -CH2-u-O-; y n es 1 o 2; y sus sales farmacéuticamente aceptables para la elaboracion de medicamentos para el tratamiento o la prevencion de los trastornos mediados por receptores mGluR5, tales como los trastornos neurologicos agudos y/o cronicos, los trastornos cognitivos y déficits de la memoria tales como enfermedad de Alzheimer, demencia senil, enfermedad de Parkinson, isquemia, corea de Huntington, esclerosis lateral amiotrofica y esclerosis multiple, enfermedades psiquiátricas tales como psicosis, epilepsia, esquizofrenia, ansiedad y depresion, y el dolor agudo y cronico; y un medicamento que contiene uno o más compuestos de formula general 1 para el tratamiento y la prevencion de estos trastornos y un medicamento que contiene uno o más de estos compuestos.
ARP070103631A 2001-03-27 2007-08-16 El uso de un compuesto derivado de imidazo[1,2-a] piridina, y un medicamento que lo contiene AR062387A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01107562 2001-03-27

Publications (1)

Publication Number Publication Date
AR062387A2 true AR062387A2 (es) 2008-11-05

Family

ID=8176948

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP020101073A AR037488A1 (es) 2001-03-27 2002-03-25 El uso de un compuesto derivado de imidazo (1,2-a) piridina, un compuesto derivado de imidazo (1,2-a) piridina, y un medicamento que contiene dicho compuesto.
ARP070103631A AR062387A2 (es) 2001-03-27 2007-08-16 El uso de un compuesto derivado de imidazo[1,2-a] piridina, y un medicamento que lo contiene

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP020101073A AR037488A1 (es) 2001-03-27 2002-03-25 El uso de un compuesto derivado de imidazo (1,2-a) piridina, un compuesto derivado de imidazo (1,2-a) piridina, y un medicamento que contiene dicho compuesto.

Country Status (17)

Country Link
US (3) US6596731B2 (es)
EP (1) EP1381363B1 (es)
JP (1) JP4088162B2 (es)
KR (1) KR100557847B1 (es)
CN (1) CN1529597A (es)
AR (2) AR037488A1 (es)
AT (1) ATE284214T1 (es)
AU (1) AU2002312768B2 (es)
BR (1) BR0208387A (es)
CA (1) CA2439291C (es)
DE (1) DE60202200T2 (es)
DK (1) DK1381363T3 (es)
ES (1) ES2232756T3 (es)
MX (1) MXPA03008525A (es)
PT (1) PT1381363E (es)
WO (1) WO2002092086A1 (es)
ZA (1) ZA200306341B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596731B2 (en) * 2001-03-27 2003-07-22 Hoffmann-La Roche Inc. Substituted imidazo[1,2-A] pyridine derivatives
WO2003055479A1 (en) * 2001-12-21 2003-07-10 Consejo Superior De Investigaciones Cientificas Compounds and their therapeutic use related to the phosphorylating activity of the enzyme gsk-3
JPWO2004035522A1 (ja) * 2002-08-30 2006-02-16 株式会社 ビーエフ研究所 プリオン蛋白蓄積性疾患の診断プローブおよび治療薬ならびにプリオン蛋白の染色剤
JP2006503038A (ja) * 2002-09-13 2006-01-26 メルク　エンド　カムパニー　インコーポレーテッド 融合ヘテロビシクロ置換フェニル代謝型グルタミン酸−５修飾因子
DE10247271A1 (de) * 2002-10-10 2004-08-26 Grünenthal GmbH Substituierte C-Imidazo[1,2-a]pyridin-3-yle
ITMI20030151A1 (it) * 2003-01-30 2004-07-31 Recordati Ind Chimica E Farma Ceutica S P A Uso di antagonisti selettivi del recettore mglu5 per il trattamento di disfunzioni neuromuscolari del tratto urinario inferiore.
US7531529B2 (en) * 2003-06-05 2009-05-12 Roche Palo Alto Llc Imidazole derivatives
WO2005060571A2 (en) * 2003-12-10 2005-07-07 Merck & Co., Inc. Antiprotozoal imidazopyridine compounds
NZ551253A (en) 2004-06-01 2010-07-30 Hoffmann La Roche Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as MGLU5 receptor antagonists
SI1863818T1 (sl) * 2005-03-23 2010-05-31 Hoffmann La Roche Derivati acetilenil pirazolo pirimidina kot antagonisti mglur
ES2340321T3 (es) 2005-09-27 2010-06-01 F.Hoffmann-La Roche Ag Oxadiazolilpirazolo-pirimidinas, como antagonistas de mglur2.
HUP0500920A2 (en) * 2005-10-05 2007-07-30 Richter Gedeon Nyrt Oxadiazole derivatives, process for their preparation and their use
EP1966201A1 (en) * 2005-11-28 2008-09-10 Mallinckrodt, Inc. Improved method of preparation for imidazolepyridines
RU2426732C2 (ru) * 2006-01-17 2011-08-20 Ф. Хоффманн-Ля Рош Аг АРИЛ-ИЗОКСАЗОЛ-4-ИЛ-ИМИДАЗО[1,2-a]ПИРИДИН, ПРИГОДНЫЙ ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА ЧЕРЕЗ ПОСРЕДСТВО GABA-РЕЦЕПТОРОВ
TW200736252A (en) 2006-01-27 2007-10-01 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
TW200803903A (en) * 2006-04-28 2008-01-16 Nihon Mediphysics Co Ltd Novel compound having affinity to amyloid
RU2008150377A (ru) * 2006-05-19 2010-06-27 Нихон Меди-Физикс Ко., Лтд. (Jp) Новое соединение, обладающее сродством к амилоиду
TW200813035A (en) 2006-06-19 2008-03-16 Astrazeneca Ab Novel heteroaryl substituted benzoxazoles
EP2042501B1 (en) * 2006-06-21 2017-04-12 Nihon Medi-Physics Co., Ltd. Compound having affinity for amyloid
TW200819458A (en) * 2006-06-23 2008-05-01 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
US20100056826A1 (en) * 2006-11-09 2010-03-04 Nihon Medi-Physicis Co., Ltd. Radioactive diagnostic imaging agent
EP2098523A4 (en) * 2006-11-17 2011-09-21 Nihon Mediphysics Co Ltd NEW, AMYLOID-AFFINE COMPOUNDS
JP5180838B2 (ja) * 2006-11-30 2013-04-10 日本メジフィジックス株式会社 新規アミロイド親和性化合物
ES2421886T3 (es) 2007-02-13 2013-09-06 Nihon Mediphysics Co Ltd Método para producción de un agente de representación de imágenes de diagnóstico por radiación
TW200901998A (en) 2007-03-06 2009-01-16 Astrazeneca Ab Novel 2-heteroaryl substituted benzothiophenes and benzofuranes
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
EP2180893B1 (en) * 2007-08-09 2014-11-12 Urifer Ltd Pharmaceutical compositions and methods for the treatment of cancer
CN103342695B (zh) 2007-09-14 2015-04-22 杨森制药有限公司 1’,3’-二取代的-4-苯基-3,4,5,6-四氢-2h,1’h-[1,4’]二吡啶-2’-酮
BRPI0817101A2 (pt) 2007-09-14 2017-05-09 Addex Pharmaceuticals Sa 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-dissubstituídas
CA2698929C (en) 2007-09-14 2016-01-19 Addex Pharma S.A. 1,3-disubstituted-4-phenyl-1h-pyridin-2-ones
EP2213672A4 (en) * 2007-10-24 2012-05-02 Nihon Mediphysics Co Ltd NEW CONNECTION WITH AFFINITY TO AMYLOID
TW200922629A (en) * 2007-10-30 2009-06-01 Nihon Mediphysics Co Ltd Utilization of novel compounds with amyloid affinity and method of producing the same
TW200922628A (en) * 2007-10-30 2009-06-01 Nihon Mediphysics Co Ltd Use of novel compound having affinity for amyloid, and process for production of the same
KR20100089858A (ko) * 2007-10-30 2010-08-12 니혼 메디피직스 가부시키가이샤 신규 아밀로이드 친화성 화합물의 사용 및 제조 방법
US7868001B2 (en) * 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
WO2009062676A2 (en) * 2007-11-14 2009-05-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EP2090576A1 (en) * 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
JP5398743B2 (ja) * 2008-05-14 2014-01-29 株式会社大塚製薬工場 ベンゼン誘導体を含むリポプロテインリパーゼ活性化組成物
WO2010025890A1 (en) 2008-09-02 2010-03-11 Ortho-Mcneil-Janssen Pharmaceuticals, Inc 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
US8697689B2 (en) 2008-10-16 2014-04-15 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
EP2373649B1 (en) 2008-11-28 2013-01-23 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
MX2011011962A (es) 2009-05-12 2012-02-28 Janssen Pharmaceuticals Inc Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostericos positivos de receptores de glutamato metabotropico (mglur2).
AU2010246609B2 (en) 2009-05-12 2013-09-05 Addex Pharma S.A. 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US8410117B2 (en) * 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
WO2012062750A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CA2814998C (en) 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
WO2015036618A1 (en) 2013-09-16 2015-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of epilepsy
SMT202100103T1 (it) 2014-01-21 2021-03-15 Janssen Pharmaceutica Nv Combinazione comprendente modulatori allosterici postivi del recettore glutammatergico metabotropico sottotipo 2 e loro utilizzo
HUE045610T2 (hu) 2014-01-21 2020-01-28 Janssen Pharmaceutica Nv 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait vagy ortosztérikus agonistáit tartalmazó kombinációk és alkalmazásuk
TWI713497B (zh) * 2015-02-26 2020-12-21 南韓商愛思開生物製藥股份有限公司 咪唑并嘧啶及咪唑并三衍生物及包含該衍生物之醫藥組成物
CN108135175B (zh) 2015-09-29 2021-04-06 肿瘤疗法科学股份有限公司 双环化合物及其用于抑制suv39h2的用途
CA3124898C (en) * 2018-12-29 2023-08-22 Wuhan Ll Science And Technology Development Co., Ltd. Heterocyclic compound, intermediate, preparation method therefor and application thereof
CN113387946B (zh) * 2021-05-17 2023-08-01 衡阳师范学院 一种超声辅助多组分合成2-苯基-3-芳胺甲基咪唑并吡啶衍生物的方法
EP4265248A1 (en) * 2022-04-22 2023-10-25 Université Paris Cité Compounds inducing production of proteins by immune cells

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3701780A (en) 1970-09-18 1972-10-31 Merck & Co Inc Imidazo(1,2-a)pyridines
JPS5341678B2 (es) 1974-03-22 1978-11-06
CH590862A5 (en) 1974-02-26 1977-08-31 Ciba Geigy Ag Isothiocyanato-substd. (2)-phenyl-imidazo (1,2-a)-pyridines prodn. - from corresp. amine and thiocarbonic acid derivs., useful as anthelmintics
JPS514194A (en) 1974-06-28 1976-01-14 Yoshitomi Pharmaceutical Imidazopirijinjudotaino seiho
JPS51125095A (en) 1974-07-23 1976-11-01 Yoshitomi Pharmaceut Ind Ltd A process for rreparing alcohol derivatives.
FR2492382A1 (fr) 1980-10-22 1982-04-23 Synthelabo Derives d'imidazo (1,2-a) pyridine, leur preparation et leur application en therapeutique
FR2525602A1 (fr) 1982-04-21 1983-10-28 Synthelabo Imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
FR2525601A1 (fr) 1982-04-21 1983-10-28 Synthelabo Derives d'imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
FR2568880B1 (fr) 1984-08-07 1986-12-12 Synthelabo Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
DE3446778A1 (de) 1984-12-21 1986-07-03 Dr. Karl Thomae Gmbh, 7950 Biberach Neue imidazoderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel
FR2581646B1 (fr) 1985-05-07 1987-09-18 Synthelabo Derives d'imidazopyridine, leur preparation et leur application en therapeutique
EP0234970B1 (fr) 1986-01-22 1991-04-17 Synthelabo Dérivés d'acylaminométhyl-3 imidazo[1,2-a]pyridines, leur préparation et leur application en thérapeutique
FR2600650B1 (fr) 1986-06-27 1988-09-09 Synthelabo Procede de preparation d'imidazopyridines et composes intermediaires
FR2606410B1 (fr) 1986-11-07 1989-02-24 Synthelabo Imidazopyridines, leur preparation et leur application en therapeutique
EP0533837A4 (en) 1990-06-12 1994-11-17 Smithkline Beecham Corp Inhibition of 5-lipoxygenase and cyclooxygenase pathway mediated diseases
IN179790B (es) * 1992-02-10 1997-12-06 Council Scient Ind Res
IN179788B (es) * 1992-02-10 1997-12-06 Council Scient Ind Res
US6054587A (en) 1997-03-07 2000-04-25 Metabasis Therapeutics, Inc. Indole and azaindole inhibitors of fructose-1,6-bisphosphatase
JPH11116481A (ja) 1997-10-06 1999-04-27 Sumitomo Pharmaceut Co Ltd スタット６活性化阻害剤
ES2151834B1 (es) 1998-08-06 2001-08-16 Sint Quimica Sa Procedimiento para preparar n,n,6-trimetil-2-(4-metilfenil)-imidazo-(1,2-a)-piridina-3-acetamida y sus sales.
EP1268478B1 (en) 2000-03-31 2007-05-02 Ortho-McNeil Pharmaceutical, Inc. Phenyl-substituted imidazopyridines
US6596731B2 (en) * 2001-03-27 2003-07-22 Hoffmann-La Roche Inc. Substituted imidazo[1,2-A] pyridine derivatives

Also Published As

Publication number Publication date
US6861437B2 (en) 2005-03-01
EP1381363B1 (en) 2004-12-08
ATE284214T1 (de) 2004-12-15
KR100557847B1 (ko) 2006-03-10
WO2002092086A1 (en) 2002-11-21
DE60202200T2 (de) 2005-12-15
KR20030083013A (ko) 2003-10-23
AU2002312768B2 (en) 2007-06-21
CN1529597A (zh) 2004-09-15
US6596731B2 (en) 2003-07-22
EP1381363A1 (en) 2004-01-21
MXPA03008525A (es) 2003-12-08
US20040180921A1 (en) 2004-09-16
US20030212096A1 (en) 2003-11-13
ZA200306341B (en) 2004-11-15
JP4088162B2 (ja) 2008-05-21
AR037488A1 (es) 2004-11-17
CA2439291C (en) 2008-01-08
PT1381363E (pt) 2005-04-29
JP2004525192A (ja) 2004-08-19
US6916826B2 (en) 2005-07-12
DK1381363T3 (da) 2005-04-18
BR0208387A (pt) 2004-06-15
DE60202200D1 (de) 2005-01-13
CA2439291A1 (en) 2002-11-21
ES2232756T3 (es) 2005-06-01
US20020188128A1 (en) 2002-12-12

Similar Documents

Publication Publication Date Title
AR062387A2 (es) El uso de un compuesto derivado de imidazo[1,2-a] piridina, y un medicamento que lo contiene
ES2940413T3 (es) Compuestos derivados de oxadiazolamina como inhibidores de histona desacetilasa 6, y la composición farmacéutica que los comprende
AR043501A1 (es) Derivados de imidazol-4-il-etinil-piridina
AR038045A1 (es) Agentes terapeuticos
UY26086A1 (es) Procedimientos e intermedios para preparar compuestos anticancerosos
AR044402A1 (es) Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen.
AR079327A1 (es) Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida
AR038044A1 (es) Compuesto derivado de pirazina, composicion farmaceutica, su uso en la fabricacion de un medicamento, proceso para su preparacion y compuesto intermediario en dicho proceso.
AR059016A4 (es) Derivados de aril-isoxazol-4-il-imidazo[1,2-a]piridina, metodo de preparacion, medicamentos que los contienen y usos en el tratamiento de trastornos cognitivos.
WO2022222966A1 (zh) 一种选择性parp1抑制剂及其应用
ECSP045229A (es) Piridinonas sustituidas como moduladores de la p38 map quinasa
AR064608A1 (es) Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer.
AR051290A1 (es) Derivados de hidantoina sustituidas
TWI568733B (zh) 新穎的唏及１，１ａ，２，７ｂ－四氫環丙烷［ｃ］唏吡啶并吡化合物
AR056470A1 (es) Sulfonamidos n- ciclicos puenteados inhibidores de gamma secretasa
BRPI0408591A (pt) derivados de 6,7,8,9-tetrahidropirimido[1,2-a] pirimidin-4-ona 8-substituìda
AR050297A1 (es) Hidantoinas sustituidas
AR057461A1 (es) Derivados de pirazol, proceso de preparacion, composiciones farmaceuticas y usos
TW201630913A (zh) 新穎環丙苯并呋喃基吡啶并吡 二酮類
CA2943011A1 (en) Halogenated quinazolin-thf-amines as pde1 inhibitors
AR051686A1 (es) Derivados de piridotienopirimidina; composiciones farmaceuticas que los contienen y su empleo en la fabricacion de un medicamento para el tratamiento de enfermedaes mediadas por inhibicion de pde4.
AR036735A1 (es) Derivados de 5-metoxi-8-aril-[1,2,4]triazolo[1,5-a]piridina
AR021900A1 (es) Derivados del cromano, sus sales y enantiomeros, un procedimiento para su preparacion y el empleo de los mismos como productos intermedios para la sintesis de medicamentos.
CO5570673A2 (es) Compuestos azapoliciclicos condensados con arilo
AR034861A1 (es) Un compuesto de indenoindolona, un procedimiento para su preparacion y una composicion farmaceutica que lo comprende

Legal Events

Date Code Title Description
FB Suspension of granting procedure